₹1,816.20
−0.07%NSE close, 16 Nov 2026
+12.32%
Beta Drugs is a small cap company, listed on NSE under the symbol BETA. At ₹1,816.20 a share, the market values the whole company at ₹2,020 crore.
In FY26, it reported sales of ₹385 crore and a net profit of ₹41 crore, an operating margin of 19.7%. Over the last three years, sales grew 19.2% a year and net profit grew 10.5% a year.
The market values the company at 37.9 times its profit over the last twelve months and 4.61 times its book value; its return on equity is 12.2% and its borrowings are 0.11 times its equity.
Promoters hold 58.91% of the shares. Foreign institutions hold 1.37%, and domestic institutions, mutual funds among them, 6.45%.
₹ crore. Consolidated figures.
| Line | 6M to Mar 2023 | 6M to Sep 2023 | 6M to Mar 2024 | Sep 2024 | 6M to Mar 2025 | 6M to Sep 2025 | Dec 2025 | Mar 2026 |
|---|
Monitoring Agency Report as on 30th September, 2026
Machine Readable / legible copy of Financial Results for the period ended 30-Sep-2026
Transcript
Link of Recording
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 115 | 141 | 154 | 180 | 182 | 204 | 87.3 | 94.0 | 126 | 137 |
|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 88.4 | 108 | 127 | 141 | 146 | 163 | 70.3 | 76.3 | 98.2 | 107 |
| Operating profit | 26.3 | 32.9 | 27.1 | 38.8 | 35.8 | 41.0 | 17.0 | 17.7 | 27.4 | 30.3 |
| Operating margin | 22.9% | 23.3% | 17.6% | 21.5% | 19.7% | 20.1% | 19.5% | 18.8% | 21.8% | 22.0% |
| Other income | 0.4 | 0.5 | 0.8 | 1.5 | 4.9 | 6.0 | 2.3 | 2.9 | 1.6 | 1.8 |
| Interest | 1.3 | 1.4 | 1.5 | 1.8 | 5.2 | 6.9 | 4.4 | 3.9 | 2.6 | 1.6 |
| Depreciation | 5.6 | 5.4 | 4.3 | 5.7 | 6.8 | 8.0 | 4.4 | 4.8 | 4.4 | 4.6 |
| Profit before tax | 19.9 | 26.6 | 22.2 | 32.8 | 24.2 | 32.1 | 10.5 | 11.8 | 22.0 | 25.8 |
| Tax | 5.0 | 6.7 | 5.6 | 8.3 | 6.2 | 8.2 | 2.0 | 2.8 | 5.6 | 6.5 |
| Net profit | 14.9 | 19.9 | 16.6 | 24.4 | 18.0 | 23.9 | 8.5 | 9.1 | 16.5 | 19.3 |
| EPS (₹) | 15.48 | 20.67 | 17.23 | 25.42 | 17.81 | 47.38 | 8.40 | 8.93 | 14.78 | 16.59 |
₹ crore, financial years to March.
| Line | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Sales | 227 | 296 | 362 | 385 |
| Expenses | 174 | 236 | 288 | 309 |
| Operating profit | 53.1 | 60.0 | 74.6 | 75.7 |
| Operating margin | 23.4% | 20.3% | 20.6% | 19.7% |
| Other income | 0.8 | 1.4 | 6.4 | 11.2 |
| Interest | 2.4 | 2.8 | 7.0 | 15.3 |
| Depreciation | 10.4 | 9.8 | 12.5 | 17.2 |
| Profit before tax | 41.1 | 48.8 | 57.0 | 54.4 |
| Tax | 10.3 | 12.3 | 14.6 | 12.9 |
| Net profit | 30.7 | 36.4 | 42.4 | 41.5 |
| EPS (₹) | 31.95 | 37.90 | 42.02 | 40.92 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY23 | FY24 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|---|
| From operations | 23.4 | 30.9 | 31.6 | 37.3 | 28.0 |
| From investing | −19.1 | −14.0 | −35.7 | −51.4 | −51.5 |
| From financing | −2.5 | −7.5 | 118 | −8.1 | 2.5 |
| Spent on fixed assets | – | – | −32.5 | −50.3 | −19.2 |
| Free cash flow | – | – | −0.9 | −13.1 | 8.8 |
Margins, returns, debt, tax and cash.
| Line | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Net margin | 13.5% | 12.3% | 11.7% | 10.8% |
| Operating margin | 23.4% | 20.3% | 20.6% | 19.7% |
| Return on equity | – | – | 21.5% | 16.9% |
| Return on capital employed | – | – | 19.4% | 17.8% |
| Return on assets | – | – | 9.7% | 8.4% |
| Debt to equity | – | – | 0.67 | 0.60 |
| Interest coverage | 18.00 | 18.30 | 9.20 | 4.60 |
| Debt to assets | – | – | 0.30 | 0.30 |
| Current ratio | – | – | 3.22 | 3.10 |
| Quick ratio | – | – | 2.64 | 2.41 |
| Cash ratio | – | – | 0.00 | 1.15 |
| Asset turnover | – | – | 0.83 | 0.78 |
| Fixed asset turnover | – | – | 4.51 | 3.34 |
| Inventory turnover | – | – | 2.90 | 2.30 |
| Receivables turnover | – | – | 3.50 | 3.20 |
| Gross margin | – | – | 52.7% | 55.5% |
| Cash from operations to profit | 76.0% | 85.0% | 74.0% | 90.0% |
| Effective tax rate | 25.2% | 25.3% | 25.5% | 23.7% |
Presentation
The financial results for the period ended September 30, 2026.
Schedule of meet
A copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 30, 2026
Azerbaijan Oncology Market Regulatory & Commercialisation update
Notice of Annual General Meeting to be held on September 30, 2026
Beta Drugs Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed from 24-Sep-2026 to 30-Sep-2026 for the purpose of ANNUAL GENERAL MEETING to be held on 30.09.2026
Notice of undefined to be held on September 30, 2026
Outcome of Board Meeting held on September 03, 2026.